Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of colorectal cancer~  * Stage IIB, III, or IV disease~* HLA-A2- or -A3-positive~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,000/mm\^3~* Hemoglobin \> 9 g/dL~* Platelet count \> 100,000/mm\^3~Hepatic~* Liver function tests ≤ 2.5 times upper limit of normal (ULN)~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known or suspected allergies to any component of the study drug~* No active connective tissue disease requiring medications~* No systemic autoimmune disease with visceral involvement~* No uncontrolled diabetes~* No other severe autoimmune disease~* No medical contraindication or potential problem that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 30 days since prior immunotherapy~* More than 30 days since prior growth factors~* More than 30 days since prior allergy shots~* No prior vaccination with any study peptides for malignancy~Chemotherapy~* More than 30 days since prior chemotherapy~Endocrine therapy~* More than 30 days since prior steroids~Radiotherapy~* More than 30 days since prior radiotherapy~Surgery~* More than 30 days since prior surgery~Other~* At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer~* No concurrent illegal drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Peptide Vaccine + Montanide + GM-CSF (Type: EXPERIMENTAL): Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).